Navigation Links
AMDeC's Vendor Program Expands Focus with Addition of BioStorage Technologies, Offering Preferred Pricing on Tissue Storage and Cold Chain Logistics Services
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire-USNewswire/ -- AMDeC, LLC announced today the expansion of its Vendor Partnership Program to include services offered by BioStorage Technologies, Inc., a global leader in scientific asset management, biomaterial storage, and cold chain logistics.  This partnership will create substantial savings for AMDeC Members through preferred pricing on biomaterial storage and relocation services offered by BioStorage Technologies. AMDeC is a consortium of 22 pre-eminent academic medical research institutions in the New York region.  

(Logo: http://photos.prnewswire.com/prnh/20100907/DC60414LOGO)

"Biomaterial storage is a costly, yet essential, part of medical research and medical care, with institutions devoting large amounts of real estate, energy resources, and staff to maintain samples," said Maria K. Mitchell, Ph.D., President of AMDeC.  "By offering our Members discounted access to services provided by BioStorage, AMDeC is helping to significantly reduce monthly expenditures and investments in capital equipment and facilities that can rapidly escalate operating costs."

BioStorage Technologies will be listed on AMDeC F.I.R.S.T.™, a real-time registry of biomedical research technology and resources accessible to AMDeC Members online.  Members will benefit from tiered pricing based on cumulative volume stored by all AMDeC Members, which could amount to savings of 30-55%, by consolidating storage and leveraging the purchasing power of the consortium to benefit hospitals and academic research institutions alike.  

The Vendor Partnership Program is one of several efforts spearheaded by AMDeC to increase efficiencies and encourage collaboration in academic medical research, especially crucial in this resource-constrained environment.  This is also an important issue for many national organizations, including
'/>"/>

SOURCE AMDeC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor
2. Leading Global CRO Selects iCardiac as Preferred Vendor
3. Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics
4. Sabalcore Computing Has Selected Scalable Informatics as Their Primary Storage Vendor
5. OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
6. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
7. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
8. MDdatacor Designated as Approved Vendor by CMS for Physician Quality Reporting Initiative
9. LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution
10. Some brain tumors mimic the genetic program of germline cells
11. Zimmer Helps Physicians and Hospitals Negotiate Emerging Health Care Business Challenges Through New Consulting Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. 22, 2014 ... leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical ... exclusive option to acquire Rhythm,s wholly owned subsidiary, Rhythm ... ghrelin agonist, for the treatment of diabetic gastroparesis and ... completed a successful Phase 2 trial of relamorelin for ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... YM BioSciences Inc. (NYSE Amex: YMI ; TSX: ... patients enrolled in the Phase I/II trial for its JAK1/JAK2 ... an oral presentation at the 52nd American Society of Hematology ... "Anemia is the most serious symptom associated with myelofibrosis, so ...
... Viruses have a bad rep—and rightly so. The ... itself makes it a destructive scourge to animals and ... the University of Maryland,s A. James Clark School of ... together by Professor Reza Ghodssi, is turning the tables, ...
... YORK, Dec. 6, 2010 See video from ... Novartis announced 24-month data showing that ... the treatment of adult patients with newly diagnosed ... chronic phase1. These new data, from the first ...
Cached Biology Technology:YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6
(Date:10/25/2014)... 2014 This report covers the specifics of ... in heavy pursuit of research due to its versatility ... to other RNA components. miRNA,s non-coding nature and ability ... for use as a biomarker for a variety of ... diagnostics for the advancement in therapeutic development. Furthermore there ...
(Date:10/25/2014)... , Oct. 23, 2014 Research ... "Biometrics Market in Europe 2014-2018" report to their ... helps to assess individuals on the basis of their ... identification of both physiological traits such as fingerprints, face ... and behavioral traits such as keystroke patterns and speech ...
(Date:10/22/2014)... , Oct. 20, 2014 The Nano-Bio ... States Air Force Research Laboratory (AFRL), has chosen a ... (AzCIM) at the University of Arizona College of Medicine ... funding.  The AzCIM project,s goal is to assess different ... collect different volumes of sweat under a variety of ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3
... fossil discovered in Tunisia represents the oldest known ancestor of ... mammals. The find is described in research published January 16 ... Julien Benoit and colleagues from the University of Science and ... cow ancestors have been found in Jamaica, but the Tunisian ...
... are facing a troubling consequence of their own success. They ... life expectancy. However, those same drugs will eventually cause the ... current treatments. With a new $3.4 million grant from ... leading a team of researchers who want to stay a ...
... launch pad or even in orbit. They start years before ... to expand our view and understanding of the planet. NASA ... for the Aerosol-Cloud-Ecosystem (ACE) mission, a satellite that "will dramatically ... clouds and aerosols," said ACE science lead David Starr of ...
Cached Biology News:Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3PODEX experiment to reshape future of atmospheric science 2PODEX experiment to reshape future of atmospheric science 3PODEX experiment to reshape future of atmospheric science 4PODEX experiment to reshape future of atmospheric science 5
... (EMSA) is a powerful tool for evaluating ... shift or gel retardation, the assay is ... to electrophoresis, free DNA will migrate differently ... Chemiluminescent EMSA Kit is a nonradioactive system ...
... The Cell Lab Quantas unique combination ... unsurpassed population resolution capabilities and accurate ... multiple excitation wavelengths, including UV, allowing ... of multi-color applications typically only achievable ...
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: